Severe eosinophilic asthma with nasal polyposis: A phenotype for improved sinonasal and asthma outcomes with mepolizumab therapy - 08/06/20
Doi : 10.1016/j.jaci.2020.02.002
Peter Howarth, MBBS, DM, FRCP a 
, Geoffrey Chupp, MD b, Linda M. Nelsen, MHS c, Eric S. Bradford, MD d, Daniel J. Bratton, PhD e, Steven G. Smith, PhD d, Frank C. Albers, MD, PhD f, ∗, Guy Brusselle, MD, PhD, FERS g, Claus Bachert, MD, PhD h
, Geoffrey Chupp, MD b, Linda M. Nelsen, MHS c, Eric S. Bradford, MD d, Daniel J. Bratton, PhD e, Steven G. Smith, PhD d, Frank C. Albers, MD, PhD f, ∗, Guy Brusselle, MD, PhD, FERS g, Claus Bachert, MD, PhD h a Global Medical, Global Specialty & Primary Care, Brentford, Middlesex, United Kingdom
b Yale Center for Asthma and Airways Disease (YCAAD), Yale School of Medicine, New Haven, Conn
c Value Evidence and Outcomes, GSK, Collegeville, Pa
d Respiratory Therapeutic Area, GSK, Research Triangle Park, NC
e Clinical Statistics, GSK, Uxbridge, Middlesex, United Kingdom
f Respiratory Medical Franchise, GSK, Research Triangle Park, NC
g Department of Respiratory Medicine, University Hospital Ghent, Ghent, Belgium
h Upper Airways Research Laboratory, University Hospital Ghent, Ghent, Belgium
| Data sharing statement: Anonymized individual participant data from the parent studies listed within this publication and their associated documents can be requested for further research from www.clinicalstudydatarequest.com. |
|
| This post hoc meta-analysis (GSK ID 208115) and the parent studies (MENSA, GSK ID MEA115588/NCT01691521; MUSCA, GSK ID 200862/NCT02281318) were funded by GlaxoSmithKline (GSK). |
|
| Disclosure of potential conflict of interests: P. Howarth, L. M. Nelsen, E. S. Bradford, D. J. Bratton, and S. G. Smith are employees of GlaxoSmithKline (GSK) and own stocks/shares in GSK. G. Chupp has served on advisory boards and speakers bureaus for AstraZeneca, Genentech, Boehringer Ingelheim, Teva, Regeneron, Circassia, and GSK, and received research grants from AstraZeneca and institutional grants from AstraZeneca, Genentech, Boehringer Ingelheim, and GSK. F. C. Albers is a former employee of GSK and holds GSK stocks/shares and is currently employed by Avillion US, Inc. G. Brusselle reports honoraria for lectures from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Novartis, Pfizer, Teva, and Zambon; and is a member of advisory boards for AstraZeneca, Boehringer Ingelheim, GSK, Novartis, Sanofi/Regeneron, and Teva. C. Bachert serves on the advisory boards of ActoBiotics, ALK, ASIT Biotech, AstraZeneca, Novartis, Sanofi, and Stallergenes. |
© 2020
Pubblicato da Elsevier Masson SAS.
Vol 145 - N° 6
P. 1713-1715 - Giugno 2020 Ritorno al numero
Articolo precedente
- Primary prevention of asthma in high-risk children using HDM SLIT: Assessment at age 6 years
- Cherry Alviani, Graham Roberts, Frances Mitchell, Jane Martin, Zaraquiza Zolkipli, Louise J. Michaelis, Pandurangan Vijayanand, Ramesh Kurukulaaratchy, S. Hasan Arshad
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?